Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:J&J) plans to split into two publically traded companies. The first company will hold the company’s prescription-drug and medical-device businesses. The second will hold the company’s consumer businesses.
So What?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
- Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
- What’s Happening With Johnson & Johnson Stock?
- Johnson & Johnson Poised For A Muted Q2?
- Cross-Sector Comparison: Is Caterpillar Stock A Better Pick Over J&J?
While J&J’s consumer business is very high profile, it lags the pharma business in terms of growth and profitability. With the planned split, J&J could potentially unlock some value for shareholders.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.